2 |
LB |
HGB |
10002272 |
Blood and lymphatic system disorders |
Anemia |
Yes - symptoms |
Hemoglobin (Hgb)
Hgb <10.0 - 8.0 g/dL; <6.2 - 4.9 mmol/L; <100 - 80g/L |
Hgb <8.0 g/dL; <4.9 mmol/L; <80 g/L; transfusion indicated |
Life-threatening consequences; urgent intervention indicated |
Death |
A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. |
|
Clarification: Definition |
|
3 |
LB |
EOS |
10014950 |
Blood and lymphatic system disorders |
Eosinophilia |
Yes |
>ULN and >Baseline |
- |
Steroids initiated |
- |
- |
A disorder characterized by laboratory test results that indicate an increased number of eosinophils in the blood. |
|
Addition: Term |
4 |
LB |
HGBMET |
10027506 |
Blood and lymphatic system disorders |
Methemoglobinemia |
Yes |
- |
>ULN |
Requiring urgent intervention |
Life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate increased methemoglobin in the blood. |
|
Addition: Term |
5 |
|
|
10019245 |
Ear and labyrinth disorders |
Hearing impaired |
Yes |
Adults enrolled on a Monitoring Program (on a 1, 2, 4, 3, 6, and 8 kHz audiogram): Threshold shift of 15 - 25 dB averaged at 2 contiguous test frequencies in at least one ear;
Adults not enrolled on a Monitoring Program: Subjective change in hearing in the absence of documented hearing loss;
Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift >20 dB hearing loss (HL) (i.e., 25 dB HL or greater); sensorineural hearing loss (SNHL) above 4 kHz (i.e., 6 or 8 kHz) in at least one ear |
Adults enrolled on a Monitoring Program (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift of >25 dB averaged at 2 contiguous test frequencies in at least one ear;
Adults not enrolled on a Monitoring Program: Hearing loss with hearing aid or intervention not indicated; limiting instrumental ADL;
Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift >20 dB at 4 kHz in at least one ear |
Adults enrolled on a Monitoring Program (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift of >25 dB averaged at 3 contiguous test frequencies in at least one ear; therapeutic intervention indicated;
Adults not enrolled on a Monitoring Program: Hearing loss with hearing aid or intervention indicated; limiting self care ADL;
Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Hearing loss sufficient to indicate therapeutic intervention, including hearing aids; threshold shift >20 dB at 2 to < 4 kHz in at least one ear |
Adults: Decrease in hearing to profound bilateral loss (absolute threshold >80 dB HL at 2 kHz and above); nonservicable hearing
Pediatric: Audiologic indication for cochlear implant; > 40 dB HL (i.e., 45 dB HL or more); SNHL at 2 kHz and above |
- |
A disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures. |
|
Clarification: Grade 1, 2, 3, 4 |
6 |
VS |
TEMP |
10016558 |
General disorders and administration site conditions |
Fever |
Yes |
38.0 - 39.0 degrees C (100.4 - 102.2 degrees F) |
>39.0 - 40.0 degrees C (102.3 - 104.0 degrees F) |
>40.0 degrees C (>104.0 degrees F) for <=24 hrs |
>40.0 degrees C (>104.0 degrees F) for >24 hrs |
Death |
A disorder characterized by elevation of the body's temperature above the upper limit of normal. |
|
|
7 |
VS |
TEMP |
10021113 |
General disorders and administration site conditions |
Hypothermia |
Yes |
- |
35 - >32 degrees C; 95 - >89.6 degrees F |
32 - >28 degrees C; 89.6 - >82.4 degrees F |
<=28 degrees C; 82.4 degrees F; life-threatening consequences (e.g., coma, hypotension, pulmonary edema, acidemia, ventricular fibrillation) |
Death |
A disorder characterized by an abnormally low body temperature. Treatment is required when the body temperature is 35C (95F) or below. |
|
|
8 |
LB |
APTT |
10000636 |
Investigations |
Activated partial thromboplastin time prolonged |
Yes |
>ULN - 1.5 x ULN |
>1.5 - 2.5 x ULN |
>2.5 x ULN; bleeding |
- |
- |
A finding based on laboratory test results in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment. |
|
Clarification: Grade 3, Definition |
9 |
LB |
ALT |
10001551 |
Investigations |
Alanine aminotransferase increased |
Yes |
>ULN - 3.0 x ULN if baseline was normal; 1.5 - 3.0 x baseline if baseline was abnormal |
>3.0 - 5.0 x ULN if baseline was normal; >3.0 - 5.0 x baseline if baseline was abnormal |
>5.0 - 20.0 x ULN if baseline was normal; >5.0 - 20.0 x baseline if baseline was abnormal |
>20.0 x ULN if baseline was normal; >20.0 x baseline if baseline was abnormal |
- |
A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen. |
Also consider Hepatobiliary disorders: Hepatic failure |
Addition: Navigational note; Clarification: Grade 1, 2, 3, 4 |
10 |
LB |
ALP |
10001675 |
Investigations |
Alkaline phosphatase increased |
Yes |
>ULN - 2.5 x ULN if baseline was normal; 2.0 - 2.5 x baseline if baseline was abnormal |
>2.5 - 5.0 x ULN if baseline was normal; >2.5 - 5.0 x baseline if baseline was abnormal |
>5.0 - 20.0 x ULN if baseline was normal; >5.0 - 20.0 x baseline if baseline was abnormal |
>20.0 x ULN if baseline was normal; >20.0 x baseline if baseline was abnormal |
- |
A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen. |
|
Clarification: Grade 1, 2, 3, 4 |
11 |
LB |
ASP |
10003481 |
Investigations |
Aspartate aminotransferase increased |
Yes |
>ULN - 3.0 x ULN if baseline was normal; 1.5 - 3.0 x baseline if baseline was abnormal |
>3.0 - 5.0 x ULN if baseline was normal; >3.0 - 5.0 x baseline if baseline was abnormal |
>5.0 - 20.0 x ULN if baseline was normal; >5.0 - 20.0 x baseline if baseline was abnormal |
>20.0 x ULN if baseline was normal; >20.0 x baseline if baseline was abnormal |
- |
A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen. |
Also consider Hepatobiliary disorders: Hepatic failure |
Addition: Navigational note; Clarification: Grade 1, 2, 3, 4 |
12 |
LB |
BICARB |
10005359 |
Investigations |
Blood bicarbonate decreased |
Yes - symptoms |
- |
- |
- |
- |
A finding based on laboratory test results that indicate a decrease in levels of bicarbonate in a venous blood specimen. |
Also consider Metabolism and nutrition disorders: Acidosis or Alkalosis |
Addition: Term, Navigational note |
|
13 |
LB |
BILI |
10005364 |
Investigations |
Blood bilirubin increased |
Yes |
>ULN - 1.5 x ULN if baseline was normal; > 1.0 - 1.5 x baseline if baseline was abnormal |
>1.5 - 3.0 x ULN if baseline was normal; >1.5 - 3.0 x baseline if baseline was abnormal |
>3.0 - 10.0 x ULN if baseline was normal; >3.0 - 10.0 x baseline if baseline was abnormal |
>10.0 x ULN if baseline was normal; >10.0 x baseline if baseline was abnormal |
- |
A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice. |
Also consider Hepatobiliary disorders: Hepatic failure |
Addition: Navigational note; Clarification: Grade 1, 2, 3, 4 |
14 |
LB |
LDH |
10005630 |
Investigations |
Blood lactate dehydrogenase increased |
Yes |
>ULN |
- |
- |
- |
- |
A finding based on laboratory test results that indicate increased levels of lactate dehydrogenase in the blood specimen. |
|
Addition: Term |
15 |
LB |
CMONOX |
10065906 |
Investigations |
Carbon monoxide diffusing capacity decreased |
Yes - symptoms |
3 - 5 units below LLN; for follow-up, a decrease of 3 - 5 units (ml/min/mm Hg) below the baseline value; asymptomatic and intervention not indicated |
6 - 8 units below LLN; for follow-up, an asymptomatic decrease of >5 - 8 units (ml/min/mm Hg) below the baseline value; symptomatic and intervention not indicated |
Asymptomatic decrease of >8 units drop; >5 units drop along with the presence of pulmonary symptoms (e.g., >Grade 2 hypoxia or >Grade 2 dyspnea); intervention indicated |
- |
- |
A finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide. |
Also consider Respiratory, thoracic and mediastinal disorders: Respiratory failure or Dyspnea |
Addition: Navigational note; Clarification: Grade 1, 2, 3 |
16 |
LB |
CD4 |
10007839 |
Investigations |
CD4 lymphocytes decreased |
Yes |
<500 - 200/mm3; <0.5 - 0.2 x 10e9 /L |
<200 - 50/mm3; <0.2 x 0.05 - 10e9 /L |
<50/mm3; <0.05 x 10e9 /L |
- |
A finding based on laboratory test results that indicate an decrease in levels of CD4 lymphocytes in a blood specimen. |
|
|
|
17 |
LB |
CHOL |
10008661 |
Investigations |
Cholesterol high |
Yes |
>ULN - 300 mg/dL; >ULN - 7.75 mmol/L |
>300 - 400 mg/dL; >7.75 - 10.34 mmol/L |
>400 - 500 mg/dL; >10.34 - 12.92 mmol/L |
>500 mg/dL; >12.92 mmol/L |
- |
A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen. |
|
|
18 |
|
|
10011268 |
Investigations |
CPK increased |
Yes |
>ULN - 2.5 x ULN |
>2.5 x ULN - 5 x ULN |
>5 x ULN - 10 x ULN |
>10 x ULN |
- |
A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen. |
Also consider Cardiac disorders: Heart failure or Cardiac disorders: Myocardial infarction. Report Cardiac disorders: Heart failure or Cardiac disorders: Myocardial infarction if same grade event. |
Addition: Navigational note |
19 |
LB |
CREAT |
10011368 |
Investigations |
Creatinine increased |
Yes |
>ULN - 1.5 x ULN |
>1.5 - 3.0 x baseline; >1.5 - 3.0 x ULN |
>3.0 x baseline; >3.0 - 6.0 x ULN |
>6.0 x ULN |
- |
A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen. |
Also consider Renal and urinary disorders: Acute kidney injury |
Addition: Navigational note; Clarification: Grade 1, 3 |
20 |
|
|
10050528 |
Investigations |
Ejection fraction decreased |
Yes |
- |
Resting ejection fraction (EF) 50 - 40%; 10 - 19% drop from baseline |
Resting ejection fraction (EF) 39 - 20%; >=20% drop from baseline |
Resting ejection fraction (EF) <20% |
- |
The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction. |
Also consider Cardiac disorders: Left ventricular systolic dysfunction. Report Cardiac disorders: Left ventricular systolic dysfunction if same grade event. |
Addition: Navigational note; Clarification: Grade 3 |
21 |
EG |
QTC |
10014383 |
Investigations |
Electrocardiogram QT corrected interval prolonged |
Yes |
Average QTc 450 - 480 ms |
Average QTc 481 - 500 ms |
Average QTc >= 501 ms; >60 ms change from baseline |
Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia |
- |
A finding of a cardiac dysrhythmia characterized by an abnormally long corrected QT interval. |
|
Clarification: Grade 1, 2, 3, 4 |
22 |
LB |
FIBRINO |
10016596 |
Investigations |
Fibrinogen decreased |
Yes |
<1.0 - 0.75 x LLN; if abnormal, <25% decrease from baseline |
<0.75 - 0.5 x LLN; if abnormal, 25 - <50% decrease from baseline |
<0.5 - 0.25 x LLN; if abnormal, 50 - <75% decrease from baseline |
<0.25 x LLN; if abnormal, 75% decrease from baseline; absolute value <50 mg/dL |
- |
A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen. |
|
Clarification: Grade 1, 2, 3, 4 |
23 |
|
|
10016987 |
Investigations |
Forced expiratory volume decreased |
Yes |
FEV1% (percentages of observed FEV1 and FVC related to their respective predicted values) 99 - 70% predicted |
FEV1 60 - 69% |
50 - 59% |
<= 49% |
- |
A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds. |
Also consider Respiratory, thoracic and mediastinal disorders: Respiratory failure or Dyspnea |
Addition: Navigational note |
24 |
LB |
GGT |
10056910 |
Investigations |
GGT increased |
Yes |
>ULN - 2.5 x ULN if baseline was normal; 2.0 - 2.5 x baseline if baseline was abnormal |
>2.5 - 5.0 x ULN if baseline was normal; >2.5 - 5.0 x baseline if baseline was abnormal |
>5.0 - 20.0 x ULN if baseline was normal; >5.0 - 20.0 x baseline if baseline was abnormal |
>20.0 x ULN if baseline was normal; >20.0 x baseline if baseline was abnormal |
- |
A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water. |
|
Clarification: Grade 1, 2, 3, 4 |
25 |
LB |
HAPTOG |
10019150 |
Investigations |
Haptoglobin decreased |
Yes |
- |
- |
- |
- |
A finding based on laboratory test results that indicate an decrease in levels of haptoglobin in a blood specimen. |
|
|
|
26 |
LB |
HGB |
10055599 |
Investigations |
Hemoglobin increased |
Yes |
Increase in >0 - 2 g/dL |
Increase in >2 - 4 g/dL |
Increase in >4 g/dL |
- |
- |
A finding based on laboratory test results that indicate increased levels of hemoglobin above normal. |
|
Clarification: Grade 1, 2, 3, Definition |
27 |
LB |
INR |
10022402 |
Investigations |
INR increased |
Yes |
>1.2 - 1.5; >1 - 1.5 x baseline if on anticoagulation; monitoring only indicated |
>1.5 - 2.5; >1.5 - 2.5 x baseline if on anticoagulation; dose adjustment indicated |
>2.5; >2.5 x baseline if on anticoagulation; bleeding |
- |
- |
A finding based on laboratory test results that indicate an increase in the ratio of the patient's prothrombin time to a control sample in the blood. |
|
Clarification: Grade 1, 2, 3 |
28 |
LB |
LIPASE |
10024574 |
Investigations |
Lipase increased |
Yes |
>ULN - 1.5 x ULN |
>1.5 - 2.0 x ULN; >2.0 - 5.0 x ULN and asymptomatic |
>2.0 - 5.0 x ULN with signs or symptoms; >5.0 x ULN and asymptomatic |
>5.0 x ULN and with signs or symptoms |
- |
A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen. |
|
Clarification: Grade 2, 3, 4 |
29 |
LB |
LYMPH |
10025256 |
Investigations |
Lymphocyte count decreased |
Yes |
<800 - 500/mm3; <0.8 - 0.5 x 10e9 /L |
<500 - 200/mm3; <0.5 - 0.2 x 10e9 /L |
<200/mm3; <0.2 x 10e9 /L |
- |
A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen. |
|
|
|
30 |
LB |
LYMPH |
10025258 |
Investigations |
Lymphocyte count increased |
Yes |
- |
>4000/mm3 - 20,000/mm3 |
>20,000/mm3 |
- |
- |
A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow. |
|
|
31 |
LB |
NEUT |
10029366 |
Investigations |
Neutrophil count decreased |
Yes |
<1500 - 1000/mm3; <1.5 - 1.0 x 10e9 /L |
<1000 - 500/mm3; <1.0 - 0.5 x 10e9 /L |
<500/mm3; <0.5 x 10e9 /L |
- |
A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen. |
|
|
|
32 |
|
|
10062646 |
Investigations |
Pancreatic enzymes decreased |
Yes |
Increase in stool frequency, bulk, or odor; steatorrhea |
Sequelae of absorption deficiency |
- |
- |
A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen. |
|
|
|
33 |
LB |
PLAT |
10035528 |
Investigations |
Platelet count decreased |
Yes |
<75,000 - 50,000/mm3; <75.0 - 50.0 x 10e9 /L |
<50,000 - 25,000/mm3; <50.0 - 25.0 x 10e9 /L |
<25,000/mm3; <25.0 x 10e9 /L |
- |
A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen. |
|
|
|
34 |
LB |
AMYLASE |
10040139 |
Investigations |
Serum amylase increased |
Yes |
>ULN - 1.5 x ULN |
>1.5 - 2.0 x ULN; >2.0 - 5.0 x ULN and asymptomatic |
>2.0 - 5.0 x ULN with signs or symptoms; >5.0 x ULN and asymptomatic |
>5.0 x ULN and with signs or symptoms |
- |
A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen. |
|
Clarification: Grade 2, 3, 4 |
35 |
LB |
TSH |
10043770 |
Investigations |
Thyroid stimulating hormone increased |
Yes |
TSH increased and no intervention initiated |
- |
- |
- |
- |
A disorder characterized by an increase in thyroid stimulating hormone. |
If intervention initiated or symptomatic, report as Endocrine disorders: Hypothyroidism. |
Addition: Term, Navigational note |
36 |
|
|
10059895 |
Investigations |
Urine output decreased |
Yes |
- |
- |
Adult: Oliguria (<80 ml in 8 hr);
Infants: < 0.5 mL/kg per hour for 24 hours;
Children: < 500 mL/1.73 m2 body surface area per day |
Adult: Anuria (<240 ml in 24 hr);
Pediatric: No urine output over 12 hours |
- |
A finding based on test results that indicate urine production is less relative to previous output. |
|
Clarification: Grade 3, 4 |
37 |
|
|
10047580 |
Investigations |
Vital capacity abnormal |
Yes |
90 - 75% of predicted value |
<75 - 50% of predicted value; limiting instrumental ADL |
<50% of predicted value; limiting self care ADL |
- |
- |
A finding based on pulmonary function test results that indicate an abnormal vital capacity (amount of exhaled after a maximum inhalation) when compared to the predicted value. |
Also consider Investigations: Forced Expiratory Volume; Respiratory, thoracic and mediastinal disorders: Respiratory failure or Dyspnea |
Addition: Navigational note |
38 |
VS |
WEIGHT |
10047896 |
Investigations |
Weight gain |
Yes |
5 - <10% from baseline |
10 - <20% from baseline |
>=20% from baseline |
- |
- |
A finding characterized by an unexpected or abnormal increase in overall body weight; for pediatrics, greater than the baseline growth curve. |
Do not use Metabolism and nutrition disorders: Obesity, this term is being retired. |
Addition: Navigational note; Clarification: Definition |
39 |
VS |
WEIGHT |
10047900 |
Investigations |
Weight loss |
Yes |
5 to <10% from baseline; intervention not indicated |
10 - <20% from baseline; nutritional support indicated |
>=20% from baseline; tube feeding or TPN indicated |
- |
- |
A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve. |
|
|
40 |
LB |
WBC |
10049182 |
Investigations |
White blood cell decreased |
Yes |
<3000 - 2000/mm3; <3.0 - 2.0 x 10e9 /L |
<2000 - 1000/mm3; <2.0 - 1.0 x 10e9 /L |
<1000/mm3; <1.0 x 10e9 /L |
- |
A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen. |
|
|
|
41 |
LB |
PH |
10000486 |
Metabolism and nutrition disorders |
Acidosis |
Yes |
pH =7.3 |
- |
pH <7.3 |
Life-threatening consequences |
Death |
A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues. |
|
|
42 |
LB |
PH |
10001680 |
Metabolism and nutrition disorders |
Alkalosis |
Yes |
pH >normal, but <=7.5 |
- |
pH >7.5 |
Life-threatening consequences |
Death |
A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues. |
|
|
43 |
LB |
CA |
10020587 |
Metabolism and nutrition disorders |
Hypercalcemia |
Yes |
Corrected serum calcium of >ULN - 11.5 mg/dL; >ULN - 2.9 mmol/L; Ionized calcium >ULN - 1.5 mmol/L |
Corrected serum calcium of >11.5 - 12.5 mg/dL; >2.9 - 3.1 mmol/L; Ionized calcium >1.5 - 1.6 mmol/L; symptomatic |
Corrected serum calcium of >12.5 - 13.5 mg/dL; >3.1 - 3.4 mmol/L; Ionized calcium >1.6 - 1.8 mmol/L; hospitalization indicated |
Corrected serum calcium of >13.5 mg/dL; >3.4 mmol/L; Ionized calcium >1.8 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium (corrected for albumin) in blood. |
|
|
44 |
LB |
K |
10020647 |
Metabolism and nutrition disorders |
Hyperkalemia |
Yes |
>ULN - 5.5 mmol/L |
>5.5 - 6.0 mmol/L; intervention initiated |
>6.0 - 7.0 mmol/L; hospitalization indicated |
>7.0 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs. |
|
Clarification: Grade 2 |
45 |
LB |
MG |
10020670 |
Metabolism and nutrition disorders |
Hypermagnesemia |
Yes |
>ULN - 3.0 mg/dL; >ULN - 1.23 mmol/L |
- |
>3.0 - 8.0 mg/dL; >1.23 - 3.30 mmol/L |
>8.0 mg/dL; >3.30 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate an elevation in the concentration of magnesium in the blood. |
|
|
46 |
LB |
NA |
10020680 |
Metabolism and nutrition disorders |
Hypernatremia |
Yes |
>ULN - 150 mmol/L |
>150 - 155 mmol/L; intervention initiated |
>155 - 160 mmol/L; hospitalization indicated |
>160 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate an elevation in the concentration of sodium in the blood. |
|
Clarification: Grade 2 |
47 |
LB |
TRIG |
10020870 |
Metabolism and nutrition disorders |
Hypertriglyceridemia |
Yes |
150 mg/dL - 300 mg/dL; 1.71 mmol/L - 3.42 mmol/L |
>300 mg/dL - 500 mg/dL; >3.42 mmol/L - 5.7 mmol/L |
>500 mg/dL - 1000 mg/dL; >5.7 mmol/L - 11.4 mmol/L |
>1000 mg/dL; >11.4 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate an elevation in the concentration of triglyceride concentration in the blood. |
|
|
48 |
LB |
URATE |
10020907 |
Metabolism and nutrition disorders |
Hyperuricemia |
Yes |
>ULN without physiologic consequences |
- |
>ULN with physiologic consequences |
Life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid. |
|
Clarification: Grade 1, 3, 4 |
49 |
LB |
ALB |
10020943 |
Metabolism and nutrition disorders |
Hypoalbuminemia |
Yes |
<3 - 2 g/dL; <30 - 20 g/L |
<2 g/dL; <20 g/L |
Life-threatening consequences; urgent intervention indicated |
Death |
A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood. |
|
|
|
50 |
LB |
CA |
10020949 |
Metabolism and nutrition disorders |
Hypocalcemia |
Yes |
Corrected serum calcium of
Corrected serum calcium of <8.0 - 7.0 mg/dL; <2.0 - 1.75 mmol/L; Ionized calcium <1.0 - 0.9 mmol/L; symptomatic |
Corrected serum calcium of <7.0 - 6.0 mg/dL; <1.75 - 1.5 mmol/L; Ionized calcium <0.9 - 0.8 mmol/L; hospitalization indicated |
Corrected serum calcium of <6.0 mg/dL; <1.5 mmol/L; Ionized calcium <0.8 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood. |
|
|
|
51 |
LB |
GLUC |
10021005 |
Metabolism and nutrition disorders |
Hypoglycemia |
Yes |
<55 - 40 mg/dL; <3.0 - 2.2 mmol/L |
<40 - 30 mg/dL; <2.2 - 1.7 mmol/L |
<30 mg/dL; <1.7 mmol/L; life-threatening consequences; seizures |
Death |
A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood. |
|
|
|
52 |
LB |
K |
10021018 |
Metabolism and nutrition disorders |
Hypokalemia |
Yes |
Symptomatic with
<3.0 - 2.5 mmol/L; hospitalization indicated |
<2.5 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood. |
|
Clarification: Grade 2 |
| |
53 |
LB |
MG |
10021028 |
Metabolism and nutrition disorders |
Hypomagnesemia |
Yes |
<1.2 - 0.9 mg/dL; <0.5 - 0.4 mmol/L |
<0.9 - 0.7 mg/dL; <0.4 - 0.3 mmol/L |
<0.7 mg/dL; <0.3 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood. |
|
|
|
54 |
LB |
NA |
10021038 |
Metabolism and nutrition disorders |
Hyponatremia |
Yes |
125-129 mmol/L and asymptomatic |
125-129 mmol/L symptomatic; 120-124 mmol/L regardless of symptoms |
<120 mmol/L; life-threatening consequences |
Death |
A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood. |
|
Addition: Grade 2; Clarification: Grade 3 |
|
55 |
|
|
10064848 |
Renal and urinary disorders |
Chronic kidney disease |
Yes |
eGFR (estimated Glomerular Filtration Rate) or CrCl (creatinine clearance) 0.5 |
eGFR or CrCl 59 - 30 ml/min/1.73 m2 |
eGFR or CrCl 29 - 15 ml/min/1.73 m2 |
eGFR or CrCl <15 ml/min/1.73 m2; dialysis or renal transplant indicated |
Death |
A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure. |
|
|
56 |
|
|
10037032 |
Renal and urinary disorders |
Proteinuria |
Yes |
1+ proteinuria; urinary protein ULN - <1.0 g/24 hrs |
Adult: 2+ and 3+ proteinuria; urinary protein 1.0 - <3.5 g/24 hrs;
Pediatric: Urine P/C (Protein/Creatinine) ratio 0.5 - 1.9 |
Adult: Urinary protein >=3.5 g/24 hrs; 4+ proteinuria;
Pediatric: Urine P/C (Protein/Creatinine) ratio >1.9 |
- |
- |
A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin. |
24-hour urine collection takes precedence over dipstick |
Addition: Navigational note; Clarification: Grade 1, 2, 3 |
57 |
|
|
10030300 |
Reproductive system and breast disorders |
Oligospermia |
Yes |
Sperm concentration > 0 to < 15 million/ml |
- |
- |
- |
- |
A disorder characterized by a decrease in the number of spermatozoa in the semen. |
|
Clarification: Grade 1; Deletion: Grade 2, 3 |
58 |
|
|
10021143 |
Respiratory, thoracic and mediastinal disorders |
Hypoxia |
Yes |
- |
Decreased oxygen saturation with exercise (e.g., pulse oximeter <88%); intermittent supplemental oxygen |
Decreased oxygen saturation at rest (e.g., pulse oximeter <88% or PaO2 <=55 mm Hg) |
Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation) |
Death |
A disorder characterized by a decrease in the level of oxygen in the body. |
|
|
59 |
VS |
|
10020772 |
Vascular disorders |
Hypertension |
Yes |
Adult: Systolic BP 120 - 139 mm Hg or diastolic BP 80 - 89 mm Hg;
Pediatric: Systolic/diastolic BP >90th percentile but< 95th percentile;
Adolescent: BP 120/80 even if < 95th percentile |
Adult: Systolic BP 140 - 159 mm Hg or diastolic BP 90 - 99 mm Hg if previously WNL; change in baseline medical intervention indicated; recurrent or persistent (>=24 hrs); symptomatic increase by >20 mm Hg (diastolic) or to >140/90 mm Hg; monotherapy indicated initiated;
Pediatric and adolescent: Recurrent or persistent (>=24 hrs) BP >ULN; monotherapy indicated; systolic and /or diastolic BP between the 95th percentile and 5 mmHg above the 99th percentile;
Adolescent: Systolic between 130-139 or diastolic between 80-89 even if < 95th percentile |
Adult: Systolic BP >=160 mm Hg or diastolic BP >=100 mm Hg; medical intervention indicated; more than one drug or more intensive therapy than previously used indicated;
Pediatric and adolescent: Systolic and/or diastolic > 5 mmHg above the 99th percentile |
Adult and Pediatric: Life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis); urgent intervention indicated |
Death |
A disorder characterized by a pathological increase in blood pressure. |
|
Clarification: Grade 1, 2, 3, 4, Definition |